产前抗抑郁药暴露与孤独症风险的生殖药物警戒高级方法Meta分析
该Meta分析纳入14项观察性研究,按比较组类型分层评估产前抗抑郁药暴露与孤独症风险的关联。基于人群的比较组显示风险升高,而精神科对照和 discordant-sibling 设计均未支持该关联,提示监测偏倚可能影响既往结果。
要点
- 基于人群比较组的设计显示产前抗抑郁药暴露与孤独症风险升高相关。
- 精神科对照和 discordant-sibling 设计均未发现显著关联。
- discordant-sibling 设计可有效控制监测偏倚。
核心结论
- 精神科对照和 discordant-sibling 设计均不支持产前抗抑郁药暴露与孤独症之间的关联。
- 基于人群比较组的设计中观察到的风险升高可能反映监测偏倚。
研究设计与样本
- 系统检索多个数据库至2017年8月,纳入14项控制观察性研究。
- 使用纽卡斯尔-渥太华量表评估研究质量,采用随机效应Meta分析。
主要发现
- 14项研究中,13项使用基于人群的比较组,5项使用精神科对照,4项使用 discordant-sibling 对照。
- 8项研究因对产前抑郁和母亲族裔控制不足被评为质量差。
- 任何抗抑郁药暴露后孤独症风险:基于人群设计 HR=1.42(95%CI=1.18,1.70),OR=1.58(95%CI=1.25,1.99)。
- 精神科对照设计 HR=1.14(95%CI=0.84,1.53),OR=1.24(95%CI=0.93,1.66);discordant-sibling 设计 HR=0.97(95%CI=0.68,1.37),OR=0.85(95%CI=0.54,1.35)。
- 选择性5-羟色胺再摄取抑制剂暴露的结果与上述相似。
关键数值与推荐
- 基于人群研究的Meta回归显示,尽管统计调整,族裔差异仍是研究异质性的显著来源。
临床怎么用
- 解读产前抗抑郁药与孤独症风险的药物警戒报告时,需考虑比较组设计对监测偏倚的影响。
- discordant-sibling 设计可有效控制监测偏倚,适用于国家登记数据库的药物警戒研究。
局限性
- 8项研究因对产前抑郁和母亲族裔控制不足被评为质量差。
- 基于人群的研究中族裔差异仍是显著异质性来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Observational studies of prenatal antidepressant safety are hindered by methodological concerns, including susceptibility to surveillance bias. Some studies address potential bias by using alternative strategies to operationalize study comparison groups. In a meta-analysis of the association between prenatal antidepressant exposure and autism risk, the authors examined the utility of comparison group operationalization in reducing surveillance bias. METHODS: A systematic search of multiple databases through August 2017 was conducted, selecting controlled observational studies of the association of prenatal antidepressant exposure with autism. Study quality was assessed using the Newcastle-Ottawa Scale. Random-effects meta-analysis produced summary effect measures with 95% confidence intervals stratified by comparator group composition, antidepressant class, and trimester of exposure. RESULTS: Fourteen studies were included, with 13 reporting results using a population-based comparison group, five using a psychiatric control group, and four using a discordant-sibling control group. Eight of the 14 studies were rated poor because of inadequate control for prenatal depression and maternal ethnicity. Autism risk estimates after prenatal exposure to any antidepressant were decidedly different for population-based designs (hazard ratio=1.42, 95% CI=1.18, 1.70; odds ratio=1.58, 95% CI=1.25, 1.99) compared with psychiatric control (hazard ratio=1.14, 95% CI=0.84, 1.53; odds ratio=1.24, 95% CI=0.93, 1.66) and discordant-sibling (hazard ratio=0.97, 95% CI=0.68, 1.37; odds ratio=0.85, 95% CI=0.54, 1.35) designs. Findings for prenatal exposure to selective serotonin reuptake inhibitors were similar. Meta-regression of population-based studies demonstrated that despite statistical adjustment, ethnicity differences remained a significant source of study heterogeneity. CONCLUSIONS: In this meta-analysis, neither psychiatric control nor discordant-sibling designs supported an association between prenatal antidepressant exposure and autism. Discordant-sibling designs effectively addressed surveillance bias in pharmacovigilance reports derived from national registries and other large databases.
引用
- Vega ML, Newport GC, Bozhdaraj D, et al. Implementation of Advanced Methods for Reproductive Pharmacovigilance in Autism: A Meta-Analysis of the Effects of Prenatal Antidepressant Exposure. Am J Psychiatry. 2020. PMID: 32375539. doi:10.1176/appi.ajp.2020.18070766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。